Logo image of CNTB

CONNECT BIOPHARMA HOLDINGS L (CNTB) Stock Fundamental Analysis

NASDAQ:CNTB - US2075231017 - ADR

1.76 USD
-0.02 (-1.12%)
Last: 8/28/2025, 8:01:32 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CNTB. CNTB was compared to 547 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CNTB as it has an excellent financial health rating, but there are worries on the profitability. CNTB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CNTB has reported negative net income.
CNTB had a negative operating cash flow in the past year.
In the past 5 years CNTB always reported negative net income.
In the past 5 years CNTB always reported negative operating cash flow.
CNTB Yearly Net Income VS EBIT VS OCF VS FCFCNTB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M -1B

1.2 Ratios

The Return On Assets of CNTB (-7.88%) is better than 84.83% of its industry peers.
With an excellent Return On Equity value of -8.66%, CNTB belongs to the best of the industry, outperforming 88.67% of the companies in the same industry.
Industry RankSector Rank
ROA -7.88%
ROE -8.66%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNTB Yearly ROA, ROE, ROICCNTB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

CNTB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTB Yearly Profit, Operating, Gross MarginsCNTB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

More info and screens

8

2. Health

2.1 Basic Checks

CNTB does not have a ROIC to compare to the WACC, probably because it is not profitable.
CNTB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CNTB Yearly Shares OutstandingCNTB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
CNTB Yearly Total Debt VS Total AssetsCNTB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

CNTB has an Altman-Z score of 2.82. This is not the best score and indicates that CNTB is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of CNTB (2.82) is better than 72.21% of its industry peers.
CNTB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.82
ROIC/WACCN/A
WACC9.7%
CNTB Yearly LT Debt VS Equity VS FCFCNTB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

CNTB has a Current Ratio of 11.46. This indicates that CNTB is financially healthy and has no problem in meeting its short term obligations.
CNTB has a better Current ratio (11.46) than 84.46% of its industry peers.
CNTB has a Quick Ratio of 11.46. This indicates that CNTB is financially healthy and has no problem in meeting its short term obligations.
CNTB's Quick ratio of 11.46 is amongst the best of the industry. CNTB outperforms 84.46% of its industry peers.
Industry RankSector Rank
Current Ratio 11.46
Quick Ratio 11.46
CNTB Yearly Current Assets VS Current LiabilitesCNTB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

More info and screens

2

3. Growth

3.1 Past

CNTB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.93%, which is quite impressive.
CNTB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.15%.
EPS 1Y (TTM)47.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-268.77%
Revenue 1Y (TTM)8.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.8%

3.2 Future

The Earnings Per Share is expected to grow by 12.46% on average over the next years. This is quite good.
The Revenue is expected to decrease by -18.18% on average over the next years. This is quite bad
EPS Next Y-328.29%
EPS Next 2Y-84.38%
EPS Next 3Y-40.01%
EPS Next 5Y12.46%
Revenue Next Year-100%
Revenue Next 2Y-35.23%
Revenue Next 3Y-10.22%
Revenue Next 5Y-18.18%

3.3 Evolution

CNTB Yearly Revenue VS EstimatesCNTB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
CNTB Yearly EPS VS EstimatesCNTB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CNTB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNTB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTB Price Earnings VS Forward Price EarningsCNTB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTB Per share dataCNTB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

A cheap valuation may be justified as CNTB's earnings are expected to decrease with -40.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-84.38%
EPS Next 3Y-40.01%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CNTB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONNECT BIOPHARMA HOLDINGS L

NASDAQ:CNTB (8/28/2025, 8:01:32 PM)

1.76

-0.02 (-1.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)N/A N/A
Inst Owners45%
Inst Owner Change-10.71%
Ins Owners0.71%
Ins Owner ChangeN/A
Market Cap97.79M
Analysts84.44
Price Target6.97 (296.02%)
Short Float %0.1%
Short Ratio0.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.13%
PT rev (3m)13.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-5.6%
EPS NY rev (3m)6.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.95
P/FCF N/A
P/OCF N/A
P/B 1.06
P/tB 1.06
EV/EBITDA N/A
EPS(TTM)-0.51
EYN/A
EPS(NY)-5.35
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0.9
BVpS1.66
TBVpS1.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.88%
ROE -8.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 113.64%
Cap/Sales 1.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.46
Quick Ratio 11.46
Altman-Z 2.82
F-Score5
WACC9.7%
ROIC/WACCN/A
Cap/Depr(3y)182.41%
Cap/Depr(5y)444.25%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-268.77%
EPS Next Y-328.29%
EPS Next 2Y-84.38%
EPS Next 3Y-40.01%
EPS Next 5Y12.46%
Revenue 1Y (TTM)8.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.8%
Revenue Next Year-100%
Revenue Next 2Y-35.23%
Revenue Next 3Y-10.22%
Revenue Next 5Y-18.18%
EBIT growth 1Y88.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.54%
OCF growth 3YN/A
OCF growth 5YN/A